Selinexor (KPT-330), an orally bioavailable analog of KPT-185, is a selective covalent CRM1 inhibitor that binds Cys528, retaining tumor suppressors in the nucleus to induce G1 arrest and apoptosis. Demonstrates potent activity against multiple myeloma. Reagent-grade; for laboratory research purposes only.
Usually ships within 24 hours.